ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO1873

Methotrexate-Induced AKI: Incidence, Risk Factors, and Recovery

Session Information

Category: Onco-Nephrology

  • 1500 Onco-Nephrology

Authors

  • Gupta, Mohit, University of Maryland Medical Center, Baltimore, Maryland, United States
  • Lin, I-Hsin, Memorial Sloan Kettering Cancer Center, New York, New York, United States
  • Latcha, Sheron, Memorial Sloan Kettering Cancer Center, New York, New York, United States
Background

Data on short and long term renal outcomes after high dose methotrexate (HD MTX) in large adult cohorts using a standardized definition of AKI is lacking. This is a report on the incidence of AKI after HD MTX, renal outcomes when HD MTX is continued after AKI, and long term renal function in patients who survived beyond 5 years after Risk factors for AKI following HD MTX were also examined.

Methods

In this single center retrospective case control study, all adult patients (>18 years) who had received HD MTX (defined as >1g/m2) from 2003 – 2013 were analyzed. AKI was identified by a >1.5x increase in baseline serum creatinine (Cr) within 4 days after HD MTX. We have collected age at first HD MTX, race, cancer, baseline and all Cr values after HD MTX, and cumulative dose (CD) of MTX. Univariable and multivariable logistic regression models were performed with AKI as the dependent variables. Overall survival for patients that had received HD MTX was presented in a Kalpan-Meier analysis.

Results

In a cohort of 865 patients, 32.1% developed AKI. Patients who developed AKI had a lower baseline Cr (0.7 ±0.2 vs 0.9 ± 0.2; p<0.001), a higher eGFR (95.1 ± 21.8 vs 90.0 ± 22.0; p<0.001) and received a higher CD (25,750 (14100 – 35000) vs 20,000 (9425 – 34,300); p<0.01). There was no statistical difference in overall survival among patients who developed AKI (p=0.13) (Figure 1) and those who continued to receive HD MTX after AKI (p=0.32) (Figure 2). Recovery from AKI to within 20% of baseline Cr was associated with a higher probability of survival (p<0.001).

Conclusion

Despite its relatively common incidence in adult patients receiving HD MTX, AKI does not affect overall survival and should not be a barrier to further administration of chemotherapy.